Lexeo brings in $95M; FDA lifts hold on Nurix cancer trial

Plus, news about Ven­tyx Bio­sciences, CEPI, Evo­lus, Re­cur­sion and Sen­so­ri­on:

Lex­eo Ther­a­peu­tics rais­es $95M: The fi­nanc­ing is near­ly the same size as the gene ther­a­py mak­er’s $100 mil­lion IPO four months ago. The new mon­ey from No­vo Hold­ings and oth­er in­vestors is ex­pect­ed to give the clin­i­cal-stage biotech run­way in­to 2027. — Kyle LaHu­cik

Nurix Ther­a­peu­tics gets FDA go-ahead to con­tin­ue tri­al: The reg­u­la­tor lift­ed its par­tial hold on Nurix’s Phase Ia/Ib clin­i­cal tri­al in­ves­ti­gat­ing NX-2127 to treat B-cell ma­lig­nan­cies. The FDA halt­ed the tri­al in No­vem­ber af­ter the com­pa­ny said it want­ed to change the man­u­fac­tur­ing process for the drug. NX-2127 works by de­grad­ing ​​BTK and IMiD neo­sub­strates. — An­na Brown

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.